Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Other Non-current Assets
Long-term assets not reported separately.
Benitec Biopharma Inc.NASDAQ: BNTC
Other Non-current Assets · Q3 FY2026 · quarter ended Mar 2026
Other non-current assets falls 25.6% from a year ago
Other non-current assets stood at $67K at the end of Q3 FY2026, down 25.6% from a year earlier and up 1.5% from the prior quarter. Over 3 fiscal years it compounded at -19.6% a year.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -25.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 83K USD
- Year-over-year change
- -4.6%
- 4-year CAGR
- -19.1%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 83K | -4.6% |
| FY2024 | 2024-06-30 | 87K | -28.7% |
| FY2023 | 2023-06-30 | 122K | -23.8% |
| FY2022 | 2022-06-30 | 160K | -17.5% |
| FY2021 | 2021-06-30 | 194K | — |
Other Non-current Assets vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 other non-current assets of $67K is the 9th highest of the 10 companies compared; the peer median is $233K.
- Its year-over-year change of -25.6% is the 4th highest of 10, against a peer median of -71.2%.
- Other non-current assets amounts to 0.0% of total assets for BNTC, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.21M | -6.7% | +5.4% | 7.4% | |
| Mar 2026 | $3.88M | -94.7% | -60.2% | 1.4% | |
| Mar 2026 | $1.42M | +14.7% | — | 0.5% | |
| Mar 2026 | $1.21M | +8.9% | -31.6% | 0.2% | |
| Mar 2026 | $233K | -71.2% | -30.5% | 0.1% | |
| Mar 2026 | $183K | -92.0% | -21.0% | 0.0% | |
| Dec 2025 | $166K | -65.1% | -91.6% | 0.0% | |
| Mar 2026 | $68K | -72.0% | -49.2% | 0.4% | |
| Mar 2026 | $67K | -25.6% | -19.6% | 0.0% | |
| Mar 2026 | $36K | -92.9% | -3.8% | 0.0% | |
| Peer median (excluding BNTC) | $233K | -71.2% | -31.1% | 0.2% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.